News for Investors and Media Listen to the replay of CEO Riad Mishlawi and CFO Khalid Nabilsi’s discussion at the #JefferiesHealthcare Conference, where they shared insights into Hikma’s growth strategy and performance across our Injectables, Branded, and Rx segments. Listen to the replay: https://lnkd.in/eCR8f-fE
Hikma Pharmaceuticals
Pharmaceutical Manufacturing
London, London 622,652 followers
At Hikma, we help put better health, within reach, every day.
About us
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at PV@hikma.com
- Website
-
http://www.hikma.com
External link for Hikma Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- London, London
- Type
- Public Company
- Founded
- 1978
- Specialties
- Oral Generics, Injectables, Generics, Manufacturing, Medicines, Healthcare, Pharmaceuticals, Nasal, Contract Manufacturing, Sterile generic injectables, Branded generics, In-licensed patented products, and Branded medicines
Locations
Employees at Hikma Pharmaceuticals
Updates
-
Meet Susana Pereira, Sr. Director Quality Systems & Validation – EU & MENA Injectables who works at Hikma Portugal, and learn more about her journey. In this series, we spotlight inspiring women at Hikma, sharing their career journeys and employee testimonials. Through insights, experiences, and leadership advice, they offer a powerful glimpse into life at Hikma and the values that drive their success. Read more here: https://lnkd.in/efvMD8Rt
-
-
Hikma Pharmaceuticals reposted this
🎉 Two decades of growth and innovation! Yesterday, we celebrated Hikma Pharmaceuticals’ 20th anniversary on our exchange. From its roots in Amman to a global healthcare leader and a FTSE 100 company, Hikma’s journey reflects the confidence of international and UK investors in its growth story and expansion. “We are proud to mark 20 years of being listed on the London Stock Exchange. This milestone reflects the enduring commitment of our people, the trust of our investors, and our dedication to manufacturing high-quality medicines,” said Said Darwazah, Executive Chairman, at the afternoon’s Market Close. Congratulations to the Hikma team.👏 🔗 https://lseg.group/4497uaQ #MarketClose #Healthcare #Pharma
-
-
-
-
-
+1
-
-
We're proud to celebrate 20 years as a publicly listed company on the London Stock Exchange. Our leadership team joined colleagues and stakeholders at the LSE for a market close ceremony to mark this significant milestone. Since listing in 2005, we’ve expanded our global footprint across North America, Europe, and the MENA region. Today, we operate 29 manufacturing facilities, R&D hubs in three key locations, offer a portfolio of over 800 products, and employ more than 9,500 people across our Injectables, Rx, and Branded businesses. This achievement is testament to the dedication and expertise of our world-class team. Each person plays a vital role in our success. Thank you to our colleagues, customers, partners, and shareholders for your continued support. Together, we look forward to the next chapter as we continue putting better health within reach, every day. Read more here: https://lnkd.in/emG4CnZp
-
-
-
-
-
+5
-
-
Discover how Hikma's unified global R&D organisation is advancing capabilities across Injectables, Respiratory, Nasal Semi-Solids and Liquids, and Oral Solids. Hear from Hafrun Fridriksdottir, EVP of Rx and R&D, in this Q&A.
-
We’re proud to partner with DGI Group LLC to bring an innovative skin tag removal solution to the #MENA region. This agreement strengthens our #ConsumerHealth portfolio and expands access to high-quality, trusted, at-home #healthcare solutions—supporting people in managing everyday health concerns safely and effectively, and helping us deliver #BetterHealth #WithinReach, #EveryDay. Read the full press release: https://brnw.ch/21wXCvw نتشرف بعقد شراكة مع مجموعة DGI Group LLC لتقديم حل مبتكر لإزالة الزوائد الجلدية في منطقة الشرق الأوسط وشمال أفريقيا. هذه الاتفاقية تعزز محفظتنا من منتجات الرعاية الصحية الاستهلاكية وتسهّل الوصول إلى حلول رعاية صحية موثوقة وعالية الجودة للمرضى في المنزل، وتدعمهم في إدارة احتياجاتهم الصحية اليومية بأمان وفعالية، وتمكّننا من توفير #صحة_أفضل #في_متناول_اليد، #كل_يوم.
-
-
Join Hikma’s CEO, Riad Mishlawi, and CFO, Khalid Nabilsi, at the #JefferiesHealthcare Conference on Wednesday, 19 November 2025, from 12:30 to 12:55 GMT. Tune in here: https://lnkd.in/exkJEZVd
I am excited to meet investors at Jefferies Healthcare Conference on Wednesday the 19th November. Alongside Khalid Nabilsi, Hikma’s CFO, we look forward to discussing Hikma’s strategic priorities across our businesses as we continue to strive towards our ambition to achieve $5 billion in revenue in 2030. In our Injectables business, we are investing significantly to build on our leadership in the US, MENA, and Europe. We are expanding capacity and developing a pipeline of more differentiated products and building our commercial capabilities to support the launch of our new speciality portfolio. In our Branded business, where we are a leading pharmaceutical company in MENA, we are expanding our impact in oncology and lifestyle-related conditions through first-to-market opportunities and robust partnerships. Meanwhile, our Hikma Rx business is driving ambitious growth in profitability in the US market, anchored by respiratory and complex generics and a growing CMO offering. Our new unified R&D structure and targeted business development efforts are enabling us to bring more complex, high-value products to market. Please come to meet us at the conference. We look forward to sharing our strategy with you.
-
News for Investors and Media Join Hikma’s CEO, Riad Mishlawi, and CFO, Khalid Nabilsi, at the #JefferiesHealthcare Conference on Wednesday, 19 November 2025, from 12:30 to 12:55 GMT. They will discuss Hikma’s strategic progress and the company’s strong growth outlook, driven by its three core business segments: Injectables, Branded, and Rx. Tune in here: https://lnkd.in/exkJEZVd Learn more about our recent results: https://lnkd.in/deyc_RVJ
-
-
On #WorldDiabetesDay, we stand with everyone living with diabetes, through every stage of life. Guided by our purpose of putting better health within reach, we continue to deliver high-quality medicines and solutions that support patients and healthcare providers to build healthier futures. Learn more: https://www.hikma.com
-
-
Today we were delighted to welcome the U.S. Ambassador to Jordan H.E. Mr. Jim Holtsnider to our MENA HQ in Amman. The discussion explored how we can further create job opportunities and improve access to essential generic medicines in the US, supported by strong Jordan–US bilateral trade relations and Hikma’s US footprint. Learn more: www.hikma.com U.S. Embassy Amman, Jordan سُعدنا اليوم باستضافة سعادة السفير الأمريكي في الأردن السيد جيم هولتسنايدر في مقرنا الإقليمي لمنطقة الشرق الأوسط وشمال أفريقيا في عمّان. حيث ناقشنا سُبُل تعزيز خلق فرص العمل وتحسين الوصول إلى الأدوية الجنيسة الأساسية في الولايات المتحدة، من خلال العلاقات التجارية الثنائية القوية بين الأردن والولايات المتحدة وحضور الحكمة في السوق الأمريكية.
-